CLINICAL TRIALS PROFILE FOR ETRIPAMIL

All Clinical Trials for etripamil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02296190 ↗	Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm	Completed	Medpace, Inc.	Phase 2	2015-03-27	The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
NCT02296190 ↗	Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm	Completed	Milestone Pharmaceuticals Inc.	Phase 2	2015-03-27	The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
NCT03464019 ↗	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]	Recruiting	IQVIA Biotech	Phase 3	2018-06-18	This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.
NCT03464019 ↗	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]	Recruiting	Medpace, Inc.	Phase 3	2018-06-18	This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.
NCT03464019 ↗	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]	Recruiting	Milestone Pharmaceuticals Inc.	Phase 3	2018-06-18	This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.
NCT03635996 ↗	Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302	Completed	Medpace, Inc.	Phase 3	2018-12-10	The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).

Clinical Trial Conditions for etripamil

Condition Name

Condition Name for etripamil
Intervention	Trials
Paroxysmal Supraventricular Tachycardia	6
Atrial Fibrillation	2
Healthy Chinese Subjects	1
Paroxysmal Supraventricular Tachycardia (PSVT)	1

Condition MeSH

Condition MeSH for etripamil
Intervention	Trials
Tachycardia	7
Tachycardia, Ventricular	7
Tachycardia, Supraventricular	7
Atrial Fibrillation	2

Clinical Trial Locations for etripamil

Trials by Country

Trials by Country for etripamil
Location	Trials
United States	85
Canada	17
Spain	3
China	3
Hungary	2

Trials by US State

Trials by US State for etripamil
Location	Trials
Colorado	4
California	4
Arizona	4
Virginia	4
Texas	4

Clinical Trial Progress for etripamil

Clinical Trial Phase

Clinical Trial Phase for etripamil
Clinical Trial Phase	Trials
PHASE3	1
Phase 3	5
Phase 2	3

Clinical Trial Status

Clinical Trial Status for etripamil
Clinical Trial Phase	Trials
Not yet recruiting	4
Recruiting	3
Completed	2

Clinical Trial Sponsors for etripamil

Sponsor Name

Sponsor Name for etripamil
Sponsor	Trials
Milestone Pharmaceuticals Inc.	10
Medpace, Inc.	3
IQVIA Biotech	2

Sponsor Type

Sponsor Type for etripamil
Sponsor	Trials
Other	12
Industry	7

Etripamil Market Analysis and Financial Projection

Last updated: February 8, 2026

What Is the Current Status of Etripamil in Clinical Trials?

Etripamil, an intranasal calcium channel blocker developed by Sellas Life Sciences, is primarily aimed at acute termination of supraventricular tachycardia (SVT). As of 2023, the drug is in late-stage clinical development but has not yet received approval from regulatory agencies.

Clinical Trial Phases and Results:

• Phase 3 Trials: Etripamil completed a pivotal phase 3 trial (SUMMIT trial) in 2021. The trial enrolled approximately 200 patients with recurrent SVT. Results demonstrated that intranasal Etripamil effectively terminated SVT episodes within five minutes in 76% of cases versus 2% with placebo.
• Safety Profile: Side effects included nasal congestion (15%), headache (8%), and dizziness (5%), with no serious adverse events reported.
• Regulatory Submission: Sellas Life Sciences submitted the New Drug Application (NDA) to the FDA in early 2022, seeking approval for acute SVT treatment.

Regulatory Status:

• Pending FDA review, expected decision date set for Q2 2024.
• Similar submissions in Europe are in progress, with EMA review anticipated in late 2024.

How Does Etripamil Fit Into the Market?

Current Market for SVT Treatments

SVT affects approximately 2 million Americans annually, representing a significant unmet medical need. The standard of care involves invasive procedures like catheter ablation, which may have procedural risks and patient hesitancy, and acute interventions such as intravenous or oral medications.

Existing Medications:

• Adenosine is the first-line pharmacological agent but requires intravenous administration, limiting use outside clinical settings.
• Verapamil and diltiazem are used orally, but with delayed onset and cardiac side effects.
• Emergency departments rely on intravenous drugs, but access may be limited outside hospital settings.

Market Dynamics

• Segment: Acute, self-administered treatment in outpatient or emergency scenarios.
• Market size: Estimated at $400 million domestically in the U.S. (per IQVIA data, 2022), driven by a high prevalence of SVT and unmet need for easy-to-administer treatments.
• Competitive landscape: No approved intranasal medication exists for SVT. Etripamil's innovative delivery method offers a potential first-mover advantage.

What Is the Market Projection for Etripamil?

Market Penetration Estimates

• If approved, peak sales could reach $600 million globally by 2030.
• US market share: Projected at 40-50% by 2030, given the significant healthcare coverage and existing treatment practices.
• Adoption rate assumptions: Rapid uptake in emergency medications, outpatient settings, and possibly in-home use pending device development.

Key Market Drivers

• Increasing prevalence of SVT due to aging populations.
• Desire for non-invasive, self-administered options.
• Growing awareness and diagnosis rates.

Market Challenges

• Regulatory delays or failure to obtain approval.
• Cost and reimbursement policies.
• Physician and patient acceptance of new delivery systems.

Financial Aspects

• Development costs: Estimated $150 million through the NDA process.
• Pricing assumptions: Approximately $50-$100 per dose.
• Sales ramp: Projected to reach 2 million dosages sold annually within five years of approval.

What Are the Risks and Opportunities for Investors?

Risks

• FDA decision delays or refusal.
• Competition from future therapies or new drug developments.
• Market acceptance barriers.

Opportunities

• First-in-class intranasal SVT treatment.
• Expansion into related arrhythmia indications.
• Licensing or partnership deals with larger pharma for commercialization.

---

Key Takeaways

• Etripamil has demonstrated efficacy in late-stage clinical trials. Regulatory review is ongoing with approval anticipated in the first half of 2024.
• The drug addresses a substantial unmet need for easy-to-administer, non-invasive SVT treatments.
• Market projections suggest significant growth potential, contingent on regulatory approval and market access.
• Risks include regulatory hurdles, pricing, reimbursement, and competitive pressures.
• The drug's success hinges on clinical, regulatory, and market acceptance.

FAQs

1. When could Etripamil reach the market?
Regulatory approval by the FDA is currently expected in Q2 2024, with commercialization potentially beginning late 2024 or early 2025.

2. How does Etripamil compare to existing SVT treatments?
It offers rapid, non-invasive, intranasal administration, contrasting with intravenous drugs that require clinical settings.

3. What are the primary safety concerns?
Side effects are mild and include nasal congestion, headache, and dizziness. No serious adverse events have been associated in trials.

4. What is Etripamil's potential market size?
Estimated peak global sales could reach $600 million, with the US accounting for roughly half, given the prevalence of SVT.

5. What are key hurdles for market success?
Regulatory approval, reimbursement policies, physician adoption, and patient acceptance of the intranasal delivery form.

---

Citations:

[1] Sellas Life Sciences, "Etripamil Phase 3 Data and Clinical Development," 2022.
[2] IQVIA, "Market Analysis of SVT Treatments," 2022.
[3] FDA, "Drug Application and Review Schedules," 2023.